SCHEMBL7678753

SCHEMBL7678753

CC(=O)OCc1ccc2oc(=O)c(C(=O)Oc3cc(Cl)ccc3Cl)cc2c1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
F2 P00734 5/20 0.77
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
MAOB P27338 5/20 0.52
CA12 O43570 2/20 0.51
CA2 P00918 2/20 0.51
CA3 P07451 2/20 0.51
CA6 P23280 2/20 0.51
CA7 P43166 2/20 0.51
CA9 Q16790 2/20 0.51
CA14 Q9ULX7 2/20 0.51
CA5B Q9Y2D0 2/20 0.51
CA4 P22748 1/20 0.51
CA5A P35218 1/20 0.50
MAOA P21397 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18752550 0.91 F2 (0.63) F2MEN1KMT2AMAOBCA12
SCHEMBL14652703 0.88 F2 (0.60) F2MEN1KMT2AMAOBCA12
SCHEMBL7691959 0.87 F2 (1.00) F2MEN1KMT2AMAOBCA12
SCHEMBL7675696 0.85 F2 (0.58) F2MEN1KMT2AMAOBCA12
SCHEMBL7679312 0.84 F2 (0.61) F2MEN1KMT2AMAOBCA12
SCHEMBL7675941 0.84 F2 (0.74) F2MEN1KMT2AMAOBCA12
SCHEMBL7679497 0.81 CA12 (0.51) F2MEN1KMT2AMAOBCA12
SCHEMBL18752216 0.81 CA12 (0.56) F2MEN1KMT2AMAOBCA12
SCHEMBL7675600 0.81 F2 (0.53) F2MEN1KMT2AMAOBCA12
SCHEMBL14652631 0.80 F2 (0.54) F2MEN1KMT2AMAOBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9814696-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-11-14 US disclosed
US-9814696-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-11-14 US disclosed
EP-2731604-B1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIV PIERRE ET MARIE CURIE PARIS 6 (FR) 2017-04-19 EP disclosed
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2017-03-09 US disclosed
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2017-03-09 US disclosed
US-9532973-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-01-03 US disclosed
US-20150182499-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2015-07-02 US disclosed
US-20150182499-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2015-07-02 US disclosed
US-9006466-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2015-04-14 US disclosed
US-9006466-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2015-04-14 US disclosed
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2014-05-29 US disclosed
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2014-05-29 US disclosed
WO-2013010963-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2013-01-24 WO disclosed
EP-2545916-A1 Use of coumarin derivatives for the preparation of drugs for treating skin diseases Universite Pierre Et Marie Curie - Paris 6 (FR) 2013-01-16 EP disclosed
US-6355658-B1 COUMARIN ESTERS WITH ETHER GROUPS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES BDKRB1, KLK1, SERPINC1 F2 77/4885MEN1 913/4885KMT2A 3807/4885
US-20150182499-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES BDKRB1, SERPINC1, KLK1 F2 76/4885MEN1 904/4885KMT2A 3749/4885
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES BDKRB1, SERPINC1, KLK1 F2 76/4885MEN1 904/4885KMT2A 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.